Tilray Inc. has been selected to supply Good Manufacturing Processes (GMP) certified medical cannabis products in France, according to the company’s press release. The selection by the French National Agency for the Safety of Medicines and Health Products (ANSM) is a milestone for the company as it seeks expansion across Europe.
- Tilray will supply the cannabis products to serve patients in need for about 18-24 months of the French experiment, beginning in the first quarter of 2021.
- The company’s products will be administered to qualifying patients for whom existing treatments do not provide sufficient relief from their symptoms and for therapeutic indications.
- Tilray has already established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels in Germany and the E.U.
Tilray is currently gaining. TLRY: NASDAQ is up 4.80% on premarket.